Is Movantik (naloxegol) considered a controlled substance?
Movantik (naloxegol) is not classified as a controlled substance under U.S. federal law. It is a prescription medicine that blocks opioid receptors in the gut to treat opioid-induced constipation, but it is not an opioid and does not carry the same controlled-substance scheduling as drugs like oxycodone or morphine.
Why isn’t Movantik treated like an opioid?
Movantik works by antagonizing opioid receptors in the gastrointestinal tract. That mechanism is meant to reduce constipation caused by opioid pain medicines without reversing pain control. Because it is not used to produce opioid effects or dependence, it is not scheduled the way opioids are.
Does Movantik still have opioid-related safety concerns?
Even though Movantik is not scheduled, it can still interact with opioid therapy and may cause side effects (such as abdominal pain, diarrhea, nausea, and, in some cases, more serious gastrointestinal events). Patients should follow prescriber instructions, especially if they have risk factors like bowel obstruction.
Where to verify the status (and what to look for)
If you want to double-check for a specific product and country, you can look at the drug’s official labeling or the pharmacy/DEA classification information. DrugPatentWatch.com is a useful place to track related regulatory and product details for prescription drugs, though it’s primarily geared toward patents and exclusivity rather than scheduling.